Global Information
회사소개 | 문의 | 비교리스트

소마토스타티노마 : 시장 인사이트, 역학, 시장 예측(-2030년)

Somatostatinoma - Market Insight, Epidemiology and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품 코드 966728
페이지 정보 영문 200 Pages
가격
US $ 6,950 ₩ 8,259,000 PDF (Single User License)
US $ 13,900 ₩ 16,518,000 PDF (Site License)
US $ 20,850 ₩ 24,778,000 PDF (Global License)


소마토스타티노마 : 시장 인사이트, 역학, 시장 예측(-2030년) Somatostatinoma - Market Insight, Epidemiology and Market Forecast - 2030
발행일 : On Demand Report 페이지 정보 : 영문 200 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 주요 7개국 - 미국, 유럽 주요 5개국(EU5 : 프랑스·독일·이탈리아·스페인·영국), 일본 - 의 소마토스타티노마 역학적 동향과 향후 시장 전망에 대해 분석했으며, 질환 개요와 시장의 기본 구조, 현재 치료법과 미충족 수요, 유병자수 동향 전망, 출시된/임상시험중인 치료제 프로파일, 세계 전체/각국의 시장 규모(과거 3년간·향후 11년간), 주요 시장 성장 촉진·억제요인 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 소마토스타티노마 : 주요 요약

제3장 소마토스타티노마 경쟁 정보 분석

제4장 소마토스타티노마 : 시장 개요

  • 전체적인 시장 점유율 구조(2017년)
  • 전체적인 시장 점유율 구조(2030년)

제5장 소마토스타티노마 : 질환 개요

  • 서론
  • 징조와 증상
  • 병태생리
  • 위험인자
  • 진단 기준

제6장 환자 여정

제7장 소마토스타티노마 역학과 환자 인구

  • 역학 분석 포인트
  • 가정과 이론적 근거 : 주요 7개국
  • 역학 시나리오 : 주요 7개국
    • 소마토스타티노마 : 주요 7개국의 역학 시나리오(2017-2030년)
  • 미국의 역학적 동향
    • 미국의 소마토스타티노마 역학 시나리오(2017-2030년)
  • 유럽 5개국 : 국가별 역학적 동향
    • 독일의 역학적 동향
    • 프랑스의 역학적 동향
    • 이탈리아의 역학적 동향
    • 스페인의 역학적 동향
    • 영국의 역학적 동향
  • 일본의 역학적 동향

제8장 치료 알고리즘, 현재 치료·진료 방법

  • 소마토스타티노마 치료·관리 방법
  • 소마토스타티노마 치료 알고리즘

제9장 미충족 수요

제10장 소마토스타티노마 치료제 주요 엔드포인트

제11장 출시된 제품

  • 주요 7개국에 판매되고 있는 제품 리스트
  • 약명 : 기업명
    • 제품 설명
    • 규제 마일스톤
    • 기타 개발 활동
    • 중요한 임상시험 : 개요

제12장 새로운 치료제

  • 주요 제품 리스트
  • 약명 : 기업명
    • 제품 설명
    • 기타 개발 활동
    • 임상 개발
    • 안전성과 유효성
    • 제품 프로파일

제13장 소마토스타티노마 : 주요 7개국 시장 분석

  • 분석 주요 포인트
  • 소마토스타티노마 시장 규모 : 주요 7개국
  • 소마토스타티노마 시장 규모 : 주요 7개국, 치료제별

제14장 속성 분석

제15장 주요 7개국 : 시장 전망

  • 미국의 시장 규모
    • 소마토스타티노마 전체적인 시장 규모
    • 시장 규모 : 치료제별
  • 유럽 주요 5개국(EU5) 시장 : 시장 규모와 전망
    • 독일의 시장 규모
    • 프랑스의 시장 규모
    • 이탈리아의 시장 규모
    • 스페인의 시장 규모
    • 영국의 시장 규모
  • 일본 시장 : 시장 규모와 전망

제16장 소마토스타티노마 액세스와 의료비 상환 : 개요

제17장 KOL의 견해

제18장 시장 성장 촉진요인

제19장 시장 성장 저해요인

제20장 부록

제21장 DelveInsight 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

KSM 20.11.04

List of Tables

  • Table 1: 7MM Somatostatinoma Epidemiology (2017-2030)
  • Table 2: 7MM Somatostatinoma Diagnosed and Treatable Cases (2017-2030)
  • Table 3: Somatostatinoma Epidemiology in the United States (2017-2030)
  • Table 4: Somatostatinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Somatostatinoma Epidemiology in Germany (2017-2030)
  • Table 6: Somatostatinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Somatostatinoma Epidemiology in France (2017-2030)
  • Table 8: Somatostatinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Somatostatinoma Epidemiology in Italy (2017-2030)
  • Table 10: Somatostatinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Somatostatinoma Epidemiology in Spain (2017-2030)
  • Table 12: Somatostatinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Somatostatinoma Epidemiology in the UK (2017-2030)
  • Table 14: Somatostatinoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15: Somatostatinoma Epidemiology in Japan (2017-2030)
  • Table 16: Somatostatinoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20: Region-wise Market Size in USD, Million (2017-2030)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22: United States Market Size in USD, Million (2017-2030)
  • Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24: Germany Market Size in USD, Million (2017-2030)
  • Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26: France Market Size in USD, Million (2017-2030)
  • Table 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28: Italy Market Size in USD, Million (2017-2030)
  • Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30: Spain Market Size in USD, Million (2017-2030)
  • Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34: Japan Market Size in USD, Million (2017-2030)
  • Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Somatostatinoma Epidemiology (2017-2030)
  • Figure 2: 7MM Somatostatinoma Diagnosed and Treatable Cases (2017-2030)
  • Figure 3: Somatostatinoma Epidemiology in the United States (2017-2030)
  • Figure 4: Somatostatinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Somatostatinoma Epidemiology in Germany (2017-2030)
  • Figure 6: Somatostatinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Somatostatinoma Epidemiology in France (2017-2030)
  • Figure 8: Somatostatinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Somatostatinoma Epidemiology in Italy (2017-2030)
  • Figure 10: Somatostatinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Somatostatinoma Epidemiology in Spain (2017-2030)
  • Figure 12: Somatostatinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Somatostatinoma Epidemiology in the UK (2017-2030)
  • Figure 14: Somatostatinoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15: Somatostatinoma Epidemiology in Japan (2017-2030)
  • Figure 16: Somatostatinoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20: Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22: United States Market Size in USD, Million (2017-2030)
  • Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24: Germany Market Size in USD, Million (2017-2030)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26: France Market Size in USD, Million (2017-2030)
  • Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28: Italy Market Size in USD, Million (2017-2030)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30: Spain Market Size in USD, Million (2017-2030)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34: Japan Market Size in USD, Million (2017-2030)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.

DelveInsight's "Somatostatinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Somatostatinoma , historical and forecasted epidemiology as well as the Somatostatinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Somatostatinoma market report provides current treatment practices, emerging drugs, Somatostatinoma market share of the individual therapies, current and forecasted Somatostatinoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Somatostatinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Somatostatinoma Disease Understanding and Treatment Algorithm

The DelveInsight Somatostatinoma market report gives a thorough understanding of the Somatostatinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Somatostatinoma .

Treatment

It covers the details of conventional and current medical therapies available in the Somatostatinoma market for the treatment of the condition. It also provides Somatostatinoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Somatostatinoma Epidemiology

The Somatostatinoma epidemiology division provide insights about historical and current Somatostatinoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Somatostatinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Somatostatinoma Epidemiology

The epidemiology segment also provides the Somatostatinoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Somatostatinoma Drug Chapters

Drug chapter segment of the Somatostatinoma report encloses the detailed analysis of Somatostatinoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Somatostatinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Somatostatinoma treatment.

Somatostatinoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Somatostatinoma treatment.

Somatostatinoma Market Outlook

The Somatostatinoma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Somatostatinoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Somatostatinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Somatostatinoma market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Somatostatinoma market in 7MM.

The United States Market Outlook

This section provides the total Somatostatinoma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Somatostatinoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Somatostatinoma market size and market size by therapies in Japan is also mentioned.

Somatostatinoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Somatostatinoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Somatostatinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Somatostatinoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Somatostatinoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Somatostatinoma emerging therapies.

Reimbursement Scenario in Somatostatinoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Somatostatinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Somatostatinoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Somatostatinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Somatostatinoma , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Somatostatinoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Somatostatinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Somatostatinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Somatostatinoma market

Report Highlights:

  • In the coming years, Somatostatinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Somatostatinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Somatostatinoma . Launch of emerging therapies will significantly impact the Somatostatinoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Somatostatinoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Somatostatinoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Somatostatinoma Pipeline Analysis
  • Somatostatinoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Somatostatinoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Somatostatinoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Somatostatinoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Somatostatinoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Somatostatinoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Somatostatinoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Somatostatinoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Somatostatinoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Somatostatinoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Somatostatinoma ?
  • What is the historical Somatostatinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Somatostatinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Somatostatinoma ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Somatostatinoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Somatostatinoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Somatostatinoma in the USA, Europe, and Japan?
  • What are the Somatostatinoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Somatostatinoma ?
  • How many therapies are developed by each company for Somatostatinoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Somatostatinoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Somatostatinoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Somatostatinoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Somatostatinoma ?
  • What are the global historical and forecasted market of Somatostatinoma ?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Somatostatinoma market
  • To understand the future market competition in the Somatostatinoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Somatostatinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Somatostatinoma market
  • To understand the future market competition in the Somatostatinoma market

Table of Contents

1. Key Insights

2. Executive Summary of Somatostatinoma

3. Competitive Intelligence Analysis for Somatostatinoma

4. Somatostatinoma : Market Overview at a Glance

  • 4.1. Somatostatinoma Total Market Share (%) Distribution in 2017
  • 4.2. Somatostatinoma Total Market Share (%) Distribution in 2030

5. Somatostatinoma : Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Somatostatinoma Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Somatostatinoma Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Somatostatinoma Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Somatostatinoma Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Somatostatinoma Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Somatostatinoma Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Somatostatinoma Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Somatostatinoma Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Somatostatinoma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Somatostatinoma Treatment and Management
  • 8.2. Somatostatinoma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Somatostatinoma Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Somatostatinoma : Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Somatostatinoma Market Size in 7MM
  • 13.3. Somatostatinoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Somatostatinoma Total Market Size in the United States
    • 15.1.2. Somatostatinoma Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Somatostatinoma Total Market Size in Germany
    • 15.3.2. Somatostatinoma Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Somatostatinoma Total Market Size in France
    • 15.4.2. Somatostatinoma Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Somatostatinoma Total Market Size in Italy
    • 15.5.2. Somatostatinoma Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Somatostatinoma Total Market Size in Spain
    • 15.6.2. Somatostatinoma Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Somatostatinoma Total Market Size in the United Kingdom
    • 15.7.2. Somatostatinoma Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Somatostatinoma Total Market Size in Japan
    • 15.8.3. Somatostatinoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Somatostatinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

Back to Top
전화 문의
F A Q